Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MOAP regimen
- Development stage
- Unknown
- Lead developer
- Han weidong
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
MOAP is a combination chemotherapy regimen being evaluated as a salvage therapy for patients with relapsed or refractory classical Hodgkin lymphoma (cHL). The regimen consists of chlormethine (an alkylating agent), vincristine (a microtubule inhibitor), doxorubicin (a topoisomerase II inhibitor and DNA intercalator), and prednisone (a glucocorticoid). It is specifically being studied by Dr. Weidong Han at the Chinese PLA General Hospital for patients who have progressed after treatment with the DP regimen (decitabine and camrelizumab). Chlormethine, the nitrogen mustard component, works by cross-linking DNA, which prevents cell replication and triggers apoptosis in the malignant cells characteristic of Hodgkin lymphoma.
- Other names
- Chlormethine + Vincristine + Doxorubicin + PrednisoneMustine + Oncovin + Adriamycin + Prednisone
Beyond the preview
Go deeper on MOAP regimen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MOAP regimen.